TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cyclophosphamide Versus Placebo in Scleroderma Lung Study
Brief Summary: To evaluate the efficacy and safety of cyclophosphamide versus placebo for the prevention and progression of symptomatic pulmonary disease in patients with systemic sclerosis.


Options:
A: Arm Label: Mycophenolate Arm; Type: EXPERIMENTAL; Interventions: Drug: Mycophenolate mofetil | Arm Label: Cyclophosphamide Arm; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide, Drug: Placebo | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): Mycophenolate Arm | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Cyclophosphamide Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cyclophosphamide Arm
B: Arm Label: mHSCT; Type: EXPERIMENTAL; Interventions: Biological: mHSCT | Arm Label: cyclophosphamide; Type: EXPERIMENTAL; Interventions: Drug: cyclophosphamide | Intervention Type: BIOLOGICAL; Name: mHSCT; Assigned to Arm(s): mHSCT | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): cyclophosphamide
C: Arm Label: stem cell trasplantation; Type: EXPERIMENTAL; Interventions: Procedure: stem cell transplantation | Arm Label: standard of care; Type: ACTIVE_COMPARATOR; Interventions: Drug: standard of care | Intervention Type: DRUG; Name: standard of care; Assigned to Arm(s): standard of care | Intervention Type: PROCEDURE; Name: stem cell transplantation; Assigned to Arm(s): stem cell trasplantation
D: Arm Label: Cylophosphamide; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Cylophosphamide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cyclophosphamide Versus Placebo in Scleroderma Lung Study
Brief Summary: To evaluate the efficacy and safety of cyclophosphamide versus placebo for the prevention and progression of symptomatic pulmonary disease in patients with systemic sclerosis.


Options:
A: Arm Label: Cylophosphamide; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Cylophosphamide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Active Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pirfenidone | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pirfenidone; Assigned to Arm(s): Active Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm
C: Arm Label: 2403 mg/day pirfenidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pirfenidone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pirfenidone; Assigned to Arm(s): 2403 mg/day pirfenidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: 2403 mg/day pirfenidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pirfenidone | Arm Label: 1197 mg/day pirfenidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pirfenidone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pirfenidone; Assigned to Arm(s): 1197 mg/day pirfenidone, 2403 mg/day pirfenidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST)
Brief Summary: The purpose of the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) is to compare the relatively new procedure of stent-assisted carotid angioplasty (CAS) to the traditional and accepted surgical approach of carotid endarterectomy (CEA) for the treatment of carotid artery stenosis to prevent recurrent strokes in those patients who have had a TIA (transient ischemic attack) or a mild stroke within the past 6 months (symptomatic) and in those patients who have not had any symptoms within the past 6 months (asymptomatic).


Options:
A: N/A
B: Arm Label: Carotid Artery Endarterectomy (CEA); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Carotid Endarterectomy (CEA) | Arm Label: Carotid Artery Stenting (CAS); Type: ACTIVE_COMPARATOR; Interventions: Device: Carotid Artery Stenting (CAS) | Intervention Type: PROCEDURE; Name: Carotid Endarterectomy (CEA); Assigned to Arm(s): Carotid Artery Endarterectomy (CEA) | Intervention Type: DEVICE; Name: Carotid Artery Stenting (CAS); Assigned to Arm(s): Carotid Artery Stenting (CAS)
C: Intervention Type: DEVICE; Name: Cordis Nitinol Stent; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: PRECISE tapered stent; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: ANGIOGUARD XP Emboli Capture Guidewire (ECGW); Assigned to Arm(s): N/A
D: Arm Label: MICHI NPS+f; Type: EXPERIMENTAL; Interventions: Device: MICHI NPS+f | Intervention Type: DEVICE; Name: MICHI NPS+f; Assigned to Arm(s): MICHI NPS+f

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST)
Brief Summary: The purpose of the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) is to compare the relatively new procedure of stent-assisted carotid angioplasty (CAS) to the traditional and accepted surgical approach of carotid endarterectomy (CEA) for the treatment of carotid artery stenosis to prevent recurrent strokes in those patients who have had a TIA (transient ischemic attack) or a mild stroke within the past 6 months (symptomatic) and in those patients who have not had any symptoms within the past 6 months (asymptomatic).


Options:
A: Arm Label: Carotid Artery Endarterectomy (CEA); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Carotid Endarterectomy (CEA) | Arm Label: Carotid Artery Stenting (CAS); Type: ACTIVE_COMPARATOR; Interventions: Device: Carotid Artery Stenting (CAS) | Intervention Type: PROCEDURE; Name: Carotid Endarterectomy (CEA); Assigned to Arm(s): Carotid Artery Endarterectomy (CEA) | Intervention Type: DEVICE; Name: Carotid Artery Stenting (CAS); Assigned to Arm(s): Carotid Artery Stenting (CAS)
B: Arm Label: Intracranial stenting group; Type: EXPERIMENTAL; Interventions: Procedure: Intracranial stenting group | Arm Label: medical group; Type: ACTIVE_COMPARATOR; Interventions: Drug: medical group | Intervention Type: PROCEDURE; Name: Intracranial stenting group; Assigned to Arm(s): Intracranial stenting group | Intervention Type: DRUG; Name: medical group; Assigned to Arm(s): medical group
C: Arm Label: aggressive medical treatment; Type: N/A; Interventions: Device: intravascular stent therapy | Intervention Type: DEVICE; Name: intravascular stent therapy; Assigned to Arm(s): aggressive medical treatment
D: Arm Label: Wingspan Stent System; Type: OTHER; Interventions: Device: Wingspan Stent System | Intervention Type: DEVICE; Name: Wingspan Stent System; Assigned to Arm(s): Wingspan Stent System

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST)
Brief Summary: The purpose of the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) is to compare the relatively new procedure of stent-assisted carotid angioplasty (CAS) to the traditional and accepted surgical approach of carotid endarterectomy (CEA) for the treatment of carotid artery stenosis to prevent recurrent strokes in those patients who have had a TIA (transient ischemic attack) or a mild stroke within the past 6 months (symptomatic) and in those patients who have not had any symptoms within the past 6 months (asymptomatic).


Options:
A: Arm Label: Intracranial stenting group; Type: EXPERIMENTAL; Interventions: Procedure: Intracranial stenting group | Arm Label: medical group; Type: ACTIVE_COMPARATOR; Interventions: Drug: medical group | Intervention Type: PROCEDURE; Name: Intracranial stenting group; Assigned to Arm(s): Intracranial stenting group | Intervention Type: DRUG; Name: medical group; Assigned to Arm(s): medical group
B: Arm Label: intensive medical management plus stenting; Type: EXPERIMENTAL; Interventions: Device: intracranial angioplasty and stenting | Arm Label: intensive medical management alone; Type: EXPERIMENTAL; Interventions: Other: intensive medical management | Intervention Type: DEVICE; Name: intracranial angioplasty and stenting; Assigned to Arm(s): intensive medical management plus stenting | Intervention Type: OTHER; Name: intensive medical management; Assigned to Arm(s): intensive medical management alone
C: Arm Label: Carotid Artery Endarterectomy (CEA); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Carotid Endarterectomy (CEA) | Arm Label: Carotid Artery Stenting (CAS); Type: ACTIVE_COMPARATOR; Interventions: Device: Carotid Artery Stenting (CAS) | Intervention Type: PROCEDURE; Name: Carotid Endarterectomy (CEA); Assigned to Arm(s): Carotid Artery Endarterectomy (CEA) | Intervention Type: DEVICE; Name: Carotid Artery Stenting (CAS); Assigned to Arm(s): Carotid Artery Stenting (CAS)
D: Arm Label: Antiplatelet; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin, Drug: clopidogrel, Other: placebo | Arm Label: Blood pressure; Type: ACTIVE_COMPARATOR; Interventions: Other: Target of Blood Pressure | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): Antiplatelet | Intervention Type: DRUG; Name: clopidogrel; Assigned to Arm(s): Antiplatelet | Intervention Type: OTHER; Name: Target of Blood Pressure; Assigned to Arm(s): Blood pressure | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Antiplatelet

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST)
Brief Summary: The purpose of the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) is to compare the relatively new procedure of stent-assisted carotid angioplasty (CAS) to the traditional and accepted surgical approach of carotid endarterectomy (CEA) for the treatment of carotid artery stenosis to prevent recurrent strokes in those patients who have had a TIA (transient ischemic attack) or a mild stroke within the past 6 months (symptomatic) and in those patients who have not had any symptoms within the past 6 months (asymptomatic).


Options:
A: Arm Label: Carotid Artery Endarterectomy (CEA); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Carotid Endarterectomy (CEA) | Arm Label: Carotid Artery Stenting (CAS); Type: ACTIVE_COMPARATOR; Interventions: Device: Carotid Artery Stenting (CAS) | Intervention Type: PROCEDURE; Name: Carotid Endarterectomy (CEA); Assigned to Arm(s): Carotid Artery Endarterectomy (CEA) | Intervention Type: DEVICE; Name: Carotid Artery Stenting (CAS); Assigned to Arm(s): Carotid Artery Stenting (CAS)
B: Arm Label: Carotid Endarterectomy (CEA); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Carotid endarterectomy (CEA) | Arm Label: Carotid Stenting (CAS); Type: ACTIVE_COMPARATOR; Interventions: Device: Carotid Stenting (CAS) | Arm Label: Intensive Medical Management - no CEA; Type: EXPERIMENTAL; Interventions: Other: Intensive Medical Management - no CEA | Arm Label: Intensive Medical Management - no CAS; Type: EXPERIMENTAL; Interventions: Other: Intensive Medical Management - no CAS | Intervention Type: PROCEDURE; Name: Carotid endarterectomy (CEA); Assigned to Arm(s): Carotid Endarterectomy (CEA) | Intervention Type: DEVICE; Name: Carotid Stenting (CAS); Assigned to Arm(s): Carotid Stenting (CAS) | Intervention Type: OTHER; Name: Intensive Medical Management - no CEA; Assigned to Arm(s): Intensive Medical Management - no CEA | Intervention Type: OTHER; Name: Intensive Medical Management - no CAS; Assigned to Arm(s): Intensive Medical Management - no CAS
C: Arm Label: Closed-cell stent (Xact stent); Type: ACTIVE_COMPARATOR; Interventions: Device: closed-cell stent (Xact stent) | Arm Label: Open-cell stent (Acculink carotid); Type: ACTIVE_COMPARATOR; Interventions: Device: Open-cell stent (Acculink carotid) | Intervention Type: DEVICE; Name: closed-cell stent (Xact stent); Assigned to Arm(s): Closed-cell stent (Xact stent) | Intervention Type: DEVICE; Name: Open-cell stent (Acculink carotid); Assigned to Arm(s): Open-cell stent (Acculink carotid)
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Carotid artery stenting with filter (interventional) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Carotid artery endarterectomy (surgical) | Intervention Type: DEVICE; Name: Carotid artery stenting with filter (interventional); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Carotid artery endarterectomy (surgical); Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Study of Fludarabine Induction Followed by CAMPATH-1H Consolidation in Untreated Patients With B-Cell Chronic Lymphocytic Leukemia
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as alemtuzumab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.

PURPOSE: Phase II trial to study the effectiveness of fludarabine followed by alemtuzumab in treating patients who have chronic lymphocytic leukemia.


Options:
A: Arm Label: Arm A (CLL/SLL subjects); Type: EXPERIMENTAL; Interventions: Drug: ABT-199 | Arm Label: Arm B (NHL subjects); Type: EXPERIMENTAL; Interventions: Drug: ABT-199 | Intervention Type: DRUG; Name: ABT-199; Assigned to Arm(s): Arm A (CLL/SLL subjects), Arm B (NHL subjects)
B: Arm Label: Fludarabine + Campath-1H; Type: EXPERIMENTAL; Interventions: Biological: alemtuzumab, Drug: fludarabine phosphate | Intervention Type: BIOLOGICAL; Name: alemtuzumab; Assigned to Arm(s): Fludarabine + Campath-1H | Intervention Type: DRUG; Name: fludarabine phosphate; Assigned to Arm(s): Fludarabine + Campath-1H
C: Intervention Type: DRUG; Name: HuMax-CD20; Assigned to Arm(s): N/A
D: Arm Label: ibrutinib; Type: EXPERIMENTAL; Interventions: Drug: Ibrutinib | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): ibrutinib

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-Label, Phase III, International Study of Subcutaneous Recombinant IL-2 in Patients With HIV-1 Infection and CD4+ Cell Counts 300/mm^3 or Greater: Evaluation of Subcutaneous Proleukin in a Randomized International Trial
Brief Summary: The purpose of this study is to see if it is effective to give HIV positive patients recombinant interleukin-2 (rIL-2) in addition to anti-HIV therapy. Patients will be followed over a minimum of 4 years to study the long-term effects of rIL-2 on their HIV disease progression.

Anti-HIV therapy has been very successful in treating HIV positive patients and in keeping viral load (level of HIV in the blood) low. However, anti-HIV drugs cannot completely rid the body of the virus, and the immune system is never completely restored in HIV positive patients. Doctors hope that giving patients recombinant interleukin-2 (rIL-2) in addition to their anti-HIV therapy will help improve their immune systems and keep them healthier over a longer period of time. rIL-2 is a hormone naturally produced by the body during an immune response to a microbial infection.


Options:
A: Arm Label: rIL-2; Type: EXPERIMENTAL; Interventions: Drug: Recombinant interleukin-2 (rIL-2) | Arm Label: No rIL-2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Recombinant interleukin-2 (rIL-2); Assigned to Arm(s): rIL-2
B: Arm Label: No IL-2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: IL-2 without ART; Type: EXPERIMENTAL; Interventions: Drug: IL-2 | Arm Label: IL-2 with pericycle HAART; Type: EXPERIMENTAL; Interventions: Drug: IL-2 | Intervention Type: DRUG; Name: IL-2; Assigned to Arm(s): IL-2 with pericycle HAART, IL-2 without ART
C: Intervention Type: DRUG; Name: Indinavir sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lamivudine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Stavudine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Zidovudine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Didanosine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Aldesleukin; Assigned to Arm(s): N/A
D: Arm Label: Antiretroviral therapy alone; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Proleukin plus antiretroviral therapy; Type: EXPERIMENTAL; Interventions: Drug: Proleukin | Intervention Type: DRUG; Name: Proleukin; Assigned to Arm(s): Proleukin plus antiretroviral therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The Diabetes Prevention Program is a nationwide clinical study to answer the question: Can Type 2 diabetes (also called noninsulin-dependent or adult-onset diabetes) be prevented or delayed? The study has recruited volunteers, who are at high risk of developing diabetes, at twenty-five medical centers in the United States. It is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, and other Institute and corporate sponsors. Researchers will evaluate the efficacy of a lifestyle intervention and a pharmacological intervention in preventing or delaying Type 2 diabetes in persons with impaired glucose tolerance (IGT). Each person in the study will be followed for 3 to 6 years.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: TV viewing reduction | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: No TV viewing reduction | Intervention Type: BEHAVIORAL; Name: No TV viewing reduction; Assigned to Arm(s): Control | Intervention Type: BEHAVIORAL; Name: TV viewing reduction; Assigned to Arm(s): 1
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Intensive Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intensive lifestyle | Intervention Type: BEHAVIORAL; Name: Intensive lifestyle; Assigned to Arm(s): Intensive Lifestyle | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Short breaks; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Short breaks | Arm Label: Long breaks; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Long breaks | Intervention Type: BEHAVIORAL; Name: Short breaks; Assigned to Arm(s): Short breaks | Intervention Type: BEHAVIORAL; Name: Long breaks; Assigned to Arm(s): Long breaks
D: Arm Label: Behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral intervention to reduce sedentary time delivered via mobile smartphone | Intervention Type: BEHAVIORAL; Name: Behavioral intervention to reduce sedentary time delivered via mobile smartphone; Assigned to Arm(s): Behavioral intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The Diabetes Prevention Program is a nationwide clinical study to answer the question: Can Type 2 diabetes (also called noninsulin-dependent or adult-onset diabetes) be prevented or delayed? The study has recruited volunteers, who are at high risk of developing diabetes, at twenty-five medical centers in the United States. It is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, and other Institute and corporate sponsors. Researchers will evaluate the efficacy of a lifestyle intervention and a pharmacological intervention in preventing or delaying Type 2 diabetes in persons with impaired glucose tolerance (IGT). Each person in the study will be followed for 3 to 6 years.


Options:
A: Intervention Type: BEHAVIORAL; Name: obesity intervention; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Intensive Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intensive lifestyle | Intervention Type: BEHAVIORAL; Name: Intensive lifestyle; Assigned to Arm(s): Intensive Lifestyle | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: High intensity intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Arm Label: Low intensity intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): High intensity intervention group, Low intensity intervention group
D: Arm Label: 1 Original Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: DPPOS Boost Lifestyle, Behavioral: Intensive Lifestyle Group Session | Arm Label: 2 Original Metformin; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Drug: Metformin, Behavioral: Intensive Lifestyle Group Session | Arm Label: 3 Original Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: Intensive Lifestyle Group Session | Intervention Type: BEHAVIORAL; Name: DPPOS Group Lifestyle; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 2 Original Metformin | Intervention Type: BEHAVIORAL; Name: DPPOS Boost Lifestyle; Assigned to Arm(s): 1 Original Lifestyle | Intervention Type: BEHAVIORAL; Name: Intensive Lifestyle Group Session; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo

Answer: B